Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05985161 · ClinicalTrials.gov registry record · Phase 2
A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors
A Phase 2 study of Solid Tumor and Wilms Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 15
- Study locations
NCT05985161 is a Phase 2 study of Solid Tumor and Wilms Tumor that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 45 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower). The trial reports 15 study locations across 9 states.
The verdict
NCT05985161, a Phase 2 study of Solid Tumor and Wilms Tumor, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
Conditions Studied
Interventions
- DRUG Selinexor
Study Locations (15)
New York
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activites) - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited protocol activities) - Montvale
California
- Children's Hospital of Los Angeles (Data Collection Only) - Los Angeles
- Stanford Medicine Children's Health (Data Collection Only) - Palo Alto
District of Columbia
- Children's National Hospital (Data Collection Only) - Washington D.C.
Georgia
- Children's Healthcare of Atlanta (Data Collection and Specimen Analysis) - Atlanta
Illinois
- Ann & Robert H. Lurie Children'S Hospital of Chicag - Chicago
Massachusetts
- Dana Farber Cancer Institute (Data Collection Only) - Boston
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05985161
The ClinicalTrials.gov registry entry for NCT05985161 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (80% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Selinexor is the first listed.
NCT05985161 reports 15 study locations spanning 9 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT05985161 about?
NCT05985161 is a clinical study titled "A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors". The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the activity of XP01.
What is the current status of trial NCT05985161?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2023-08-01. Estimated completion is 2029-08-01.
What conditions does trial NCT05985161 study?
This clinical trial studies the following conditions: Solid Tumor, Wilms Tumor, Rhabdoid Tumor, Malignant Peripheral Nerve Sheath Tumors, MPNST.
What interventions are being tested in trial NCT05985161?
The interventions under investigation include: Selinexor (DRUG).
Who is sponsoring clinical trial NCT05985161?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05985161 being conducted?
This trial has 15 study locations across California, District of Columbia, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
RECRUITING · Phase 2
-
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
RECRUITING · Phase 2
-
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors
RECRUITING · Phase 2
-
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.